Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atriplex lentiformis pollen extract is a non-standardized allergenic biologic derived from the pollen of the *Atriplex lentiformis* plant, commonly known as quailbrush. Developed by ALK-Abello and distributed by Greer Laboratories, this extract is utilized for both diagnostic and therapeutic purposes in clinical allergy practice. For diagnosis, it is administered via percutaneous or intradermal skin testing to identify IgE-mediated sensitivity in patients with a history of seasonal allergies. For treatment, it is used in subcutaneous allergen immunotherapy (hyposensitization) to reduce allergic symptoms by modulating the immune response, specifically by inducing the production of allergen-specific IgG antibodies and reducing IgE-mediated responses to the quailbrush pollen allergens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atriplex lentiformis pollen extract.